Black Diamond Therapeutics, Inc. (BDTX) Hit a 52 Week High, Can the Run Continue?

Company Performance - Black Diamond (BDTX) has seen a significant increase in its stock price, rising 28.5% over the past month and achieving a new 52-week high of $4.03 [1] - Year-to-date, Black Diamond's stock has gained 83.2%, outperforming the Zacks Medical sector's 1.5% and the Zacks Medical - Biomedical and Genetics industry's 8.1% [1] Earnings and Forecast - The company has a strong track record of positive earnings surprises, beating the Zacks Consensus Estimate in the last four quarters [2] - In the latest earnings report on August 7, 2025, Black Diamond reported an EPS of -$0.19, surpassing the consensus estimate of -$0.25 [2] - For the current fiscal year, Black Diamond is expected to post earnings of $0.33 per share on revenues of $70 million [2] Valuation Metrics - Black Diamond currently trades at 11.7X current fiscal year EPS estimates, which is below the peer industry average of 20X [5] - The stock has a Value Score of C, Growth Score of B, and Momentum Score of B, resulting in a combined VGM Score of B [5] Zacks Rank - Black Diamond holds a Zacks Rank of 1 (Strong Buy) due to rising earnings estimates, indicating strong potential for further gains [6] - The recommendation is to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, which applies to Black Diamond [6] Industry Comparison - The Medical - Biomedical and Genetics industry is performing well, ranking in the top 37% of all industries, providing favorable conditions for both Black Diamond and its peer, Exact Sciences Corporation (EXAS) [9] - Exact Sciences Corporation has a Zacks Rank of 1 (Strong Buy) and is expected to post earnings of $0.36 per share on revenues of $3.16 billion for the current fiscal year [8]